ArticleJournal of clinical microbiology2003
Bacterial diversity in cases of lung infection in cystic fibrosis patients: 16S ribosomal DNA (rDNA) length heterogeneity PCR and 16S rDNA terminal restriction fragment length polymorphism profiling.
Article in Journal of clinical microbiology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 111 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
111 citing papers in PubMed, 2 syntheses or guidelines pooled it, 233 citations in OpenAlex.
- Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis.The Cochrane database of systematic reviews · 2020Pooled it
- Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis.The Cochrane database of systematic reviews · 2016Pooled it
- DNA sequencing for microbial surveillance in cystic fibrosis airways: advances, challenges, and clinical translation.Clinical microbiology reviews · 2026Review
- The redefined identity ofJournal of bacteriology · 2026Review
- The Role of the Respiratory Microbiome in Pneumonia.Clinics in chest medicine · 2026Review
- Remodelling of cystic fibrosis respiratory microbiota in response to extended elexacaftor-tezacaftor-ivacaftor therapy.Microbiome · 2026Article
- Toroidal displacement ofmBio · 2025Article
- The multifaced role of the macrophage migration inhibitory factor family in organ fibrosis.American journal of physiology. Cell physiology · 2025Review
- Bacterial interactions underpin worsening lung function in cystic fibrosis-associated infections.mBio · 2025Article
- Interactions between Pseudomonas aeruginosa and six opportunistic pathogens cover a broad spectrum from mutualism to antagonism.Environmental microbiology reports · 2024Article
- Comparative microbiome analysis in cystic fibrosis and non-cystic fibrosis bronchiectasis.Respiratory research · 2024Article
- Ecological patterns and processes of temporal turnover within lung infection microbiota.Microbiome · 2024Article
- IntestinalmBio · 2024Article
- The presence of cystic fibrosis-related diabetes modifies the sputum microbiome in cystic fibrosis disease.American journal of physiology. Lung cellular and molecular physiology · 2024Article
- The Airway Microbiome-IL-17 Axis: a Critical Regulator of Chronic Inflammatory Disease.Clinical reviews in allergy & immunology · 2023Review
- Diagnosis and Management of Cystic Fibrosis Exacerbations.Seminars in respiratory and critical care medicine · 2023Review
- Molecular Accounting and Profiling of Human Respiratory Microbial Communities: Toward Precision Medicine by Targeting the Respiratory Microbiome for Disease Diagnosis and Treatment.International journal of molecular sciences · 2023Review
- Community composition shapes microbial-specific phenotypes in a cystic fibrosis polymicrobial model system.eLife · 2023Article
- Bacterial Culture Underestimates Lung Pathogen Detection and Infection Status in Cystic Fibrosis.Microbiology spectrum · 2022Article
- Exploring the Cystic Fibrosis Lung Microbiome: Making the Most of a Sticky Situation.Journal of the Pediatric Infectious Diseases Society · 2022Review
51 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The leading cause of morbidity and mortality in cystic fibrosis (CF) patients stems from repeated bacterial respiratory infections. Many bacterial species have been cultured from CF specimens and so are associated with lung disease. Despite this, much remains to be determined. In the present study, we characterized without prior cultivation the total bacterial community present in specimens taken from adult CF patients, extracting DNA directly from 14 bronchoscopy or sputum samples. Bacterial 16S ribosomal DNA (rRNA) gene PCR products were amplified from extracted nucleic acids, with analyses by terminal restriction fragment length polymorphism (T-RFLP), length heterogeneity PCR (LH-PCR), and sequencing of individual cloned PCR products to characterize these communities. Using the same loading of PCR products, 12 distinct T-RFLP profiles were identified that had between 3 and 32 T-RFLP bands. Nine distinct LH-PCR profiles were identified containing between one and four bands. T-RFLP bands were detected in certain samples at positions that corresponded to pathogens cultured from CF samples, e.g., Burkholderia cepacia and Haemophilus influenzae. In every sample studied, one T-RFLP band was identified that corresponded to that produced by Pseudomonas aeruginosa. A total of 103 16S rRNA gene clones were examined from five patients. P. aeruginosa was the most commonly identified species (59% of clones). Stenotrophomonas species were also common, with eight other (typically anaerobic) bacterial species identified within the remaining 17 clones. In conclusion, T-RFLP analysis coupled with 16S rRNA gene sequencing is a powerful means of analyzing the composition and diversity of the bacterial community in specimens sampled from CF patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.